The “poison pill” makes a takeover suddenly more expensive
A common anti-takeover defense is called a shareholder rights plan, often nicknamed a poison pill. Rather than having the board sell a huge block of stock directly, the plan gives existing shareholders rights to buy additional shares at a steep discount if a potential buyer crosses a specified ownership threshold. The would-be acquirer is typically excluded from that offer.
If other shareholders use their rights, the company has more shares outstanding. The buyer’s existing holdings then represent a smaller percentage of the company, so gaining control requires buying many more shares—often at a much higher total cost.
The threat can matter before anyone buys a share
The plan is designed to change the buyer’s calculation. A bidder that wants to avoid triggering it may have to negotiate with the board instead of building a large stake or pressing ahead with an unsolicited offer. The board can use that time to assess the bid, seek a better price, or look for another option.
The pill is therefore less like a permanent lock on the company than a costly obstacle that can give directors leverage. Its effectiveness depends on the plan’s terms and on whether shareholders, courts, or other constraints limit how the board can use it.
Protection comes with a governance tradeoff
A defense can help prevent a company from being bought too cheaply or too quickly. But it can also make it harder for shareholders to accept a bid they consider attractive, giving directors more control over the outcome. The central tension is whether the extra time protects shareholders’ interests—or mainly protects the people already running the company.
